Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the availability of Koshine826 PRO 1% for hair loss treatment. The discussion includes Minoxidil, finasteride, and RU58841.

A user switched from topical to oral finasteride and is seeking additional topical treatments for hair growth besides minoxidil. They are aware of stemoxydine and caffeine solutions and are asking for more recommendations.

An Instagram page is stealing hair loss progress pictures to advertise a scam product. Users suggest watermarking images and reporting the account.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

The conversation is about trying Keratin Microsphere products for hair loss, specifically SAF 100 Pro, but no noticeable results were observed. The user also mentioned using a Hairclub wand.

The conversation discusses hair loss treatments, specifically using finasteride and minoxidil, and emphasizes taking proactive steps rather than blaming external factors. It also touches on the reality of side effects and the importance of trying treatments to find what works.

Sodium Laureth Sulfate (SLS) in shampoos and its potential impact on thinning hair. The user follows a regimen of shampoo, keto shampoo, and conditioner, seeking suggestions for better products.

Shiseido's S-DSC Hair Multiplication Treatment in Japan is available to foreigners but is expensive and not very effective. Despite past disappointments, there is hope for future treatments with more options in development beyond Minoxidil and Finasteride.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

Pelage received $120 million for phase 3 of PP405, a potential hair loss treatment, but there is skepticism about its success. Some users believe any improvement over finasteride is a win, while others expect full hair regrowth.

The conversation is about finding a source for RU58841 in Canada as an additional treatment for hair loss, alongside oral minoxidil and dutasteride. Alternatives like kx826 are suggested, with some users discussing prices and sources for these products.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

Hair loss treatments, specifically Pyrilutamide and Minoxidil/Finasteride/RU58841. Participants discussed their experiences with them and the results they have seen so far.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

Athletes often use finasteride to maintain hair transplants, but some avoid it due to potential hormonal effects. Notable examples include Mo Salah and Conor McGregor, while LeBron James has had multiple procedures with varying success.

The conversation discusses skepticism about a new hair loss treatment called project K, which claims to replicate a chemical from UCLA research but is suspected to be a scam. The original poster plans to continue using oral minoxidil, finasteride, and dutasteride, along with microneedling, for hair regrowth.

The conversation is about finding sources for compounded minoxidil and tretinoin. Users suggest "Happy Head" and "ulo" as options.

The user experienced visible hair improvement after using oral minoxidil (5 mg daily) and finasteride (1 mg daily) for less than a year, with no noticeable side effects. They encourage others to try these treatments if they notice signs of hair loss.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.